Search

Displaying results 4621 - 4630 of 10000 in total
  1. Drug

    Ferrous ascorbate

    go.drugbank.com/drugs/DB14490
    ApprovedWithdrawn

    Synonyms: Iron(2+) L-ascorbate, L-Ascorbic acid, iron complexCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Turmeric

    go.drugbank.com/drugs/DB14276
    ApprovedInvestigational

    Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Synonyms: Yu JinCategories: Compounds used in a research, industrial, or household setting
  3. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous … solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

    Synonyms: (4-((1S)-1-(Aminomethyl)-2-(isoquinolin-6-ylamino)-2-oxoethyl)phenyl)methyl 2,4- dimethylbenzoate
  4. Drug

    Phenylacetic acid

    go.drugbank.com/drugs/DB09269
    Approved

    Because it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China. … Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.

    Synonyms: ANTINEOPLASTON AS 2-1 COMPONENT PHENYLACETIC ACID, α-toluic acidCategories: Ammonium Ion Binding Activity
  5. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    _PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.

    Synonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Categories: Cytochrome P-450 CYP2B6 Inducers, Heterocyclic Compounds, 1-Ring
  6. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN HISTOCOMPATIBILITY ANTIGEN HLA-DR) (HUMAN-MOUSE MONOCLONAL HU1D10.GAMMA.(SUB 1)-CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL HU1D10 LIGHT CHAIN, DIMER
  7. Drug

    Epinastine

    go.drugbank.com/drugs/DB00751
    Approved

    It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding … Epinastine is used for the prevention of itching associated with allergic conjunctivitis.

    Synonyms: 3-amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepineMixtures: FLURINOL(R) D COMPRIMIDOS DE LIBERACION MODIFICADA
  8. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.

  9. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Dihydrotachysterol

    go.drugbank.com/drugs/DB01070
    ApprovedWithdrawn

    A vitamin D that can be regarded as a reduction product of vitamin D2.

    Categories: Vitamin D and Analogues